Document is current
Any future updates will be listed below
-
Authors
Hsu, Robert https://orcid.org/0000-0003-3957-6106
Al-zubeidy, Batul
Flores, Daniel
Nazarian, Ari
Baugh, Aaron
Gonzalez, Edgar
Castanon, Sofi
Xiu, Joanne
Kang, Irene
Spicer, Darcy
Lenz, Heinz Josef
Dara, Lily
Ademuyiwa, Foluso O.
Korn, W. Michael
Irshad, Sheeba
Chan, Isaac S.
Roussos Torres, Evanthia T.
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30 CA014089)
Concern Foundation
Tower Cancer Research Foundation
University of Southern California
- License Information
-
More Information
Article History
Received: 5 August 2023
Accepted: 9 February 2024
First Online: 20 April 2024
Declarations
:
: RH was a consultant for Targeted Oncology and received honoraria from DAVA Oncology and The Dedham Group. JX is an employee of Caris Life Sciences. IK has received consulting fees from Caris Life Sciences and Gilead. HJL has received honoraria from serving as consultant or on advisory board for Merck Serono, Bayer, and Genentech. FOA has received consultant fees from Teledoc Health, AstraZenecea, QED Therapeutics, Immunomedics, Cardinal Health, Athenex, Biotheranostics and research funding from Pfizer, Immunomedics, NeoImmuneTech, RNA Diagnostics, and Astellas Pharma. WMK has stock in Caris Life Sciences. All other authors have no potential conflicts of interest.
